Navigation Links
Intradigm Announces Issuance of RNA Interference (RNAi) Patent Covering Potent siRNA Sequence
Date:5/19/2009

First Patent to be Issued from Among Intradigm's Large Collection of Pending siRNA Sequence Patents

PALO ALTO, Calif., May 19 /PRNewswire/ -- Intradigm Corporation, a leading developer of targeted, systemic RNA interference (RNAi) therapeutics, today announced the issuance of United States patent 7,534,878, titled "Composition and Methods of RNAi Therapeutics for Treatment of Cancer and Other Neovascularization Diseases." The issued patent covers a specific double-stranded siRNA sequence that is directed against the angiogenic pathway and which possesses therapeutic potential in the treatment of cancer. This is the first patent to be issued to Intradigm related to an active pharmaceutical ingredient in the RNAi space and is one of a significant number of pending patent applications worldwide covering proprietary Intradigm siRNA sequences against more than 50 clinically relevant targets.

As Intradigm's first issued piece of intellectual property (IP) related to an active pharmaceutical ingredient, this patent supplements the company's existing patent portfolio, providing Intradigm issued IP in each of the three essential areas of RNAi therapeutic development: target sequences, delivery and siRNA structural features. Based on this broad IP portfolio, Intradigm is in a uniquely strong position within the RNAi therapeutic industry, particularly among other private companies in the space.

"With the continued rapid maturation of the RNAi industry, it is critical that Intradigm properly protect the breakthroughs that are being pioneered in our labs. As we continue to take important steps to execute our strategy, we find ourselves in the enviable position of possessing one of the industry's broadest and strongest RNAi IP portfolios," said Philip Haworth, chief executive officer of Intradigm. "With today's development, we have further broadened and strengthened this position and can now claim to have a portfolio
'/>"/>

SOURCE Intradigm Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards
2. NxStage Announces Strategic Business Alliance with Asahi Kasei Kuraray Medical
3. Beckman Coulter, Inc. Announces Common Stock Offering
4. Games for Health Conference Announces First Cognitive Health Track Powered by SharpBrains
5. The Quigley Corporation Announces Update on Strategic Alternatives and Commitment to Additional Review of Current Cost Structure
6. Neurocrine Announces Full Year Results from 603 Study (Petal Study) of Elagolix for Treatment of Endometriosis Pain
7. Coalition for Pulmonary Fibrosis Announces Awards and Activities at ATS International Conference
8. GNAX/AtlantaNAP Announces Newest Client, Health Information Designs
9. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
10. AMR Research Announces Final Agenda for Sold-Out Supply Chain Executive Conference
11. International Student Insurance Announces Website Redesign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... D.C. (PRWEB) August 27, 2014 A ... Neurosurgery discusses the importance of time in correcting coagulopathy ... focuses on a variety of anticoagulants and examines medical ... According to the research, although anticoagulants have been approved ... and systemic embolism, they are also known to affect ...
(Date:8/27/2014)... President Obama is considering Executive action ... White House initiative that supplies green cards and work ... also open a pathway to Social Security benefits, warns ... to work authorization would add new long-term liabilities to ... the target of proposals to cut the growth in ...
(Date:8/27/2014)... PCOS (Polycystic Ovarian Syndrome) affects an estimated ... for a number of health disorders and medical conditions. ... even within the medical community. Many women are suffering ... excess body fat around the waist area (truncal obesity), ... caused by PCOS. , Awareness is the first step ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 ... PartnerTech AB, a major systems integration and electronics ... Cryotherapy offering the first U.S. designed and ... offered the ideal combination of manufacturing expertise, location, ... system. Impact Cryotherapy, headquartered in Atlanta, GA, offers ...
(Date:8/27/2014)... *Anyone who is interested in learning more about the clinical ... on the web ( http://www.availclinical.com ) or contact them directly at ... by fibromyalgia – a condition characterized by a broad range ... pain , Joint stiffness , Muscle ... Depression , Anxiety , While no ...
Breaking Medicine News(10 mins):Health News:Flood Law Group Comments on Recent AAICH Study 2Health News:The Senior Citizens League (TSCL) Warns: White House Action On Immigration Could Give Social Security To Known Illegals 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 2Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 3Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 4Health News:Houston 5k Supports Women With PCOS, Sponsored by Amerejuve MedSpa 5Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 2Health News:PartnerTech Inc. and Impact Cryotherapy Announce Made in America Manufacturing Initiative 3Health News:Avail Clinical Research is Looking for Qualified Individuals Who Are Interested in Participating in a Fibromyalgia Clinical Trial Near Orlando, Florida 2Health News:Avail Clinical Research is Looking for Qualified Individuals Who Are Interested in Participating in a Fibromyalgia Clinical Trial Near Orlando, Florida 3
... NEW YORK, March 11 In this 90 minute episode, ... out what happened,after they left treatment. Drew reveals who has ... The audience, which is comprised of,recovering addicts and fans of ... questions about what happened over the season., ...
... - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer of ... the operating room, today announced that Dr. Arun,Menawat, ... corporate story,technology and highlights, including an update on ... Co. Healthcare Conference. The conference,runs Monday, March 17 ...
... tumors by more than half, study found , , TUESDAY, ... the 60 percent of women with breast cancer whose malignancies ... letrozole (Femara) can cut risk of a recurrence by more ... initiated the drug one to seven years after they stopped ...
... TALLAHASSEE, Fla., March 11 Based on,overwhelming response, ... FSDDS,Florida Sun Defense Essay Contest have been extended ... Dermatology and Dermatologic Surgery,(FSDDS), the contest is designed ... about the importance of sun safety. Four overall,winners ...
... AARP Services Inc. and,Genworth Financial, Inc. (NYSE: ... a,new long term care insurance plan for AARP,s ... affordable alternative to traditional,long term care insurance and ... with more states anticipated., (Logo: http://www.newscom.com/cgi-bin/prnh/20070209/NYF043LOGO ...
... 11 Verathon(R) is pleased to,announce a new ... 9400,bladder volume instrument with patent-pending NeuralHarmonics(TM),Technology. Small Child ... noninvasively on children weighing less than 60 pounds ... same instrument used for adult,patients. This enhanced BladderScan(R) ...
Cached Medicine News:Health News:Novadaq to present at Cowen Healthcare Conference 2Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 2Health News:Late Use of Aromatase Inhibitor Still Effective Against Breast Cancer 3Health News:Deadline Extended for Essay Submissions to the FSDDS Sun Defense Essay Contest Throughout Florida Elementary Schools 2Health News:AARP Services Inc. and Genworth Financial Introduce New Innovative and Affordable Long Term Care Insurance Option to AARP Members 2Health News:AARP Services Inc. and Genworth Financial Introduce New Innovative and Affordable Long Term Care Insurance Option to AARP Members 3Health News:AARP Services Inc. and Genworth Financial Introduce New Innovative and Affordable Long Term Care Insurance Option to AARP Members 4Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 2Health News:Verathon Inc. Launches Enhanced BladderScan(R) Bladder Volume Instrument With Small Child Mode 3
(Date:8/26/2014)... Using publicly released 2015 rate filings in ... five common specialty drugs. Specialty drugs have been ... costs and shortage of generic alternatives. They treat ... and are used for a broad variety of ... HealthPocket found that among 2015 Obamacare ...
(Date:8/26/2014)... ALISO VIEJO, Calif. , Aug. 26, 2014 ... ) today announced the enrollment of the first ... the efficacy, safety and tolerability of AVP-786 for ... AVP-786 is a novel investigational drug consisting of ... dose quinidine. "There are millions of ...
(Date:8/26/2014)... Calif. , Aug. 26, 2014  Based on its ... Sullivan recognizes Volpara Solutions with the 2014 North American Frost ... an innovative range of volumetric breast imaging solutions for the ... the company has steadily introduced several new solutions and has ... States , Europe , ...
Breaking Medicine Technology:2015 Platinum Plans Are Best Buy for Consumers Using Expensive Specialty Drugs 2Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 2Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 3Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 4Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 5Avanir Pharmaceuticals Announces Initiation of Phase II Study of AVP-786 for the Adjunctive Treatment of Major Depressive Disorder 6Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 2Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 3Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 4Frost & Sullivan Applauds Volpara Solutions' Clear Vision in Identifying the Importance of Dose Tracking and Quantitative Analytics in the Early Detection of Breast Cancer 5
... 12, 2011 Breast Imaging facilities looking ... benefit from the exceptional image quality of the Aspire™ ... Medical Systems U.S.A., Inc. Now FDA 510(k) cleared, the ... of potential abnormalities that not only assists in more ...
... 2011 Henry Schein, Inc., (NASDAQ: ... services to office-based practitioners, announced today that Steven ... will present at the Morgan Stanley Global Healthcare Conference.  The ... City.   Henry Schein,s presentation is scheduled to ...
Cached Medicine Technology:Fujifilm's Aspire HD Receives FDA Clearance 2Fujifilm's Aspire HD Receives FDA Clearance 3Henry Schein to Present at the Morgan Stanley Global Healthcare Conference 2
Sterile perfluorocarbon for intraocular Application....
Sterile Silicone Oil for Intraocular Application....
Alcon offers medical grade perfluoropropane (SF6) intraocular gases for ophthalmological use....
Silikon 1000 (purified polydimethylsiloxane) is a highly purified long chain polydimethylsiloxane trimethylsiloxy terminated silicone oil. For use as a postoperative retinal tamponade during vitreore...
Medicine Products: